Clinical Trials

  • Principal Investigator:

    Robert J. Sommer, MD
    The purpose of this study is to collect more information about the GORE CARDIOFORM Septal Occluders (GSO device) treatment to close the Patent Foramen Ovale (PFO) to reduce the risk for another stroke.
  • Principal Investigator:

    Ajay J. Kirtane, MD
    RADIANCE II is a randomized, double-blind, sham-controlled, single cohort study designed todemonstrate the effectiveness (how well it works) and safety of the Paradise Renal Denervation System in hypertensive subjects (subjects with high blood pressure).
  • Principal Investigator:

    Tamim M. Nazif, MD
    This prospective, multicenter trial is looking at the investigative device called the ACURATE Transcatheter Aortic Valve System for TAVR to see if it is safe and effective in treating patients with severe symptomatic native aortic stenosis. The ACURATE Transcatheter Aortic Valve System for TAVR is designed for iliofemoral access and delivery of a self-expanding implant that restores competency in a sclerotic aortic valve. To implant the device, a surgical incision is made in the femoral vein (incision in the upper leg between the knee and the hip). A catheter is advanced into the heart access...
  • Principal Investigator:

    Susheel Kumar Kodali, MD
    This is designed for patients with severe, symptomatic mitral regurgitation who are not candidates for conventional mitral repair.
  • Principal Investigator:

    Susheel Kumar Kodali, MD
    This is a prospective, multi-center open label first in human clinical study aimed at demonstrating safety and technical performance of the Cardiovalve device to minimize tricuspid regurgitation. Tricuspid regurgitation is a disorder in which the valve does not close tight enough. This problem causes blood to flow backward into the right upper heart chamber (atrium) when the right lower heart chamber (ventricle) contracts. The purpose is to evaluate the safety and technical performance of the Cardiovalve System to successfully treat patients with severe tricuspid regurgitation. The tricuspid...
  • Principal Investigator:

    Robert J. Sommer, MD
    This is a prospective, randomized, multi-center global investigational study. The primary objective is to determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants (NOACs - drugs that inhibits clotting) in patients with Atrial Fibrillation (AF) - irregular heart rhythm caused by other things, such as high blood pressure or an overactive thyroid gland.
  • Principal Investigator:

    Susheel Kumar Kodali, MD
    The goal of this early feasibility study is to gain initial insight into the basic safety and performance of transluminal (through the blood vessels) implantation of the PASCAL Systems implant (composed of man-made materials). We are trying to evaluate the safety and performance of the PASCAL System with Optimal Medical Therapy (OMT) (also known as standard of care) compared to OMT alone in participants withsymptomatic severe tricuspid regurgitation who may not be ideal candidates for tricuspid valve surgery (tricuspid valve repair that is performed via openheart surgery) and may be eligible...
  • Principal Investigator:

    Amardeep S. Saluja, MD
    This study is a prospective, randomized, multi-center, global investigation to determine if left atrial appendage closure with the WATCHMAN FLX Device is a reasonable alternative to oral anticoagulation in patients after AF ablation.
  • Principal Investigator:

    Muredach Patrick Reilly, MBBCh
    While the biobank can support research of many different diseases and conditions, we are focusing our research now on COVID-19. This research is being conducted to help to advance our understanding of the COVID-19 virus, including but not limited to: how the virus is spread, potential vaccines or other treatments, genetic susceptibility to severe disease, and other questions that will come up as we continue our research studies. CUB will facilitate this research by providing biological samples and medical information to Columbia-NYP researchers and our collaborators around the world who are...
  • Principal Investigator:

    Susheel Kumar Kodali, MD
    The study is designed to to compare the safety and effectiveness of the PASCAL System to the MitraClip System for reduction of degenerative mitral regurgitation.

Pages